Form 4: United Therapeutics CEO Executes Pre-Planned Stock Sales

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, executed a pre-arranged 10b5-1 plan, exercising stock options and selling common stock.

Summary

• Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (UTHR), exercised 9,500 stock options at an exercise price of $146.03 per share.
• Concurrently, Rothblatt sold 9,500 shares of common stock at weighted average prices ranging from $581.74 to $602.7167 per share.
• These transactions were conducted on March 30, 2026, as part of a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.
• Following these transactions, Rothblatt directly holds 40,513 shares of common stock and indirectly holds 166 shares by spouse, 324,518 shares by Trust (20), 258,117 shares by Trust (21), 45,596 shares by Trust (22), and 10,962 shares by Trust (23).
• Rothblatt also beneficially owns 40,500 derivative stock options, with 1,734,410 stock options remaining under the 10b5-1 plan, which expire on March 17, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine, pre-planned insider transaction under a 10b5-1 plan, which is common practice and does not typically signal a change in company fundamentals or management's outlook.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a structured and transparent approach to insider stock sales, reducing concerns about opportunistic selling.
• The sale prices significantly exceed the exercise price of the stock options, indicating a substantial gain for the reporting person.

Negatives

• The sale of shares by a high-ranking executive, even if pre-planned, represents a reduction in direct insider ownership.

Future Outlook

The 10b5-1 trading plan is set to continue until the earlier of the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026, indicating further pre-planned transactions are expected.

Industry Context

StockSavvy.ai notes that pre-arranged 10b5-1 trading plans are a common mechanism for corporate insiders in the biotechnology and pharmaceutical sectors, like United Therapeutics, to sell company stock in a compliant manner, mitigating accusations of trading on material non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 plan aligns with best practices for executive stock transactions, similar to those employed by executives at major pharmaceutical companies such as Pfizer or Johnson & Johnson, ensuring transparency and compliance with SEC regulations.
• The significant difference between the option exercise price and the sale price is typical for long-tenured executives in successful growth companies within the biotech industry, reflecting the appreciation of the company's stock over time.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of direct insider ownership, but the pre-planned nature mitigates negative sentiment. The overall impact on the company's stock price is likely minimal given the routine nature of the transaction.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The 10b5-1 trading plan will continue until the earlier of the exercise of 1,734,410 stock options or December 31, 2026, implying further pre-scheduled transactions.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction (exercise of options and sale of shares) under a 10b5-1 plan. Such transactions are generally not indicative of a change in the company's fundamental outlook or performance. Therefore, a seasoned investor would likely maintain their current position, as this event alone does not provide new information warranting a change in investment strategy.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Executive Compensation, Biotechnology